Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.
BioGend Therapeutics Co (ROCO:6733) Volatility Explanation
Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.
Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.
Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
BioGend Therapeutics Co Volatility Related Terms
ROCO:6733 vs VRTX, REGN, ALNY: Volatility Comparison
For the Biotechnology subindustry, BioGend Therapeutics Co's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGend Therapeutics Co Volatility vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioGend Therapeutics Co's Volatility distribution charts can be found below:
* The bar in red indicates where BioGend Therapeutics Co's Volatility falls into.
BioGend Therapeutics Co (ROCO:6733) Volatility Calculation
The annualized volatility is calculated as following:
σA
=
σM
*
√12
=
√ 1/(n-1) ∑(Ri - R')^2
*
√12
Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGend Therapeutics Co (ROCO:6733) has a Volatility of 66.12% as of Jul. 14, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on BioGend Therapeutics Co and its competitors.
Is BioGend Therapeutics Co's Volatility too high?
BioGend Therapeutics Co's current Volatility is 66.12%. Overall, BioGend Therapeutics Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGend Therapeutics Co's Volatility compare to VRTX and REGN?
BioGend Therapeutics Co's Volatility of 66.12% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on BioGend Therapeutics Co and its competitors. BioGend Therapeutics Co's current Volatility is 66.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGend Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BioGend Therapeutics Co (ROCO:6733) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$70.22, compared to a current price of NT$25.35 — trading 63.9% below its estimated fair value. The current Volatility is 66.12%. BioGend Therapeutics Co's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For BioGend Therapeutics Co (ROCO:6733), the current Volatility is 66.12% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGend Therapeutics Co (ROCO:6733) Overvalued in 2026?
Based on GuruFocus' analysis, BioGend Therapeutics Co stock appears to be undervalued.
The current stock price of NT$25.35 is trading 63.9% below its estimated GF Value™ of NT$70.22.
GuruFocus considers BioGend Therapeutics Co to be Significantly Undervalued.
Key valuation signals for ROCO:6733:
Volatility: 66.12%
GF Value™: NT$70.22 vs. price of NT$25.35 (63.9% below fair value)
No single metric tells the full story. See the ROCO:6733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGend Therapeutics Co Ltd is a Taiwan-based company involved in the research and development of orthopedic medical equipment and related products, and the sale of related products. It is involved in the research and development of inventive cartilage repair technology and products, adipose stem cell extraction technology, and others. Geographically, the company generates a majority of its revenue from Taiwan, followed by China, Malaysia, and other regions.
73GF Score
Get the complete analysis for ROCO:6733
Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6733 has been successfully added to your 
